Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06718257

Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma

This study aims to validate the efficacy and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma through a multicenter, retrospective study to guide clinical practice.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cholangiocarcinoma Adenocarcinoma Carcinoma Neoplasms Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

This study plans to enroll patients diagnosed with advanced cholangiocarcinoma. After confirming patients treated with GP/GEMOX or GP/GEMOX combined with PD-1/L1 and TKI agents as initial therapy, the investigators will collect relevant clinical data, including basic clinical information, laboratory data, imaging data, pathological data, and surgical data through an electronic medical record system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically or radiologically confirmed intrahepatic cholangiocarcinoma
  • Initially treated with GP/GEMOX or GP/GEMOX combined with PD-1/L1 and TKI inhibitors

Exclusion criteria

  • Direct surgery after hospitalization
  • Initial treatment combined with local therapies (radiotherapy, radiofrequency, particle implantation, TACE, etc.)
  • Initial treatment involving other comprehensive therapeutic regimens

Treatment and study plan

Gemcitabine combined with cisplatin or oxaliplatin

Drug

Gemcitabine (1000 mg/m², day 1 and 8) and cisplatin (75 mg/m², day 1) or oxaliplatin (85 mg/m², day 1)

Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors

Drug

Gemcitabine (1000 mg/m², day 1 and 8), cisplatin (75 mg/m²; day 1) or oxaliplatin (85 mg/m²; day 1), PD-1/L1 agents (200 mg; day 1), and TKI inhibitors (8 mg; per day)

Primary outcomes

  1. Overall survival (OS)

    Time frame: 1 year

    Overall survival (OS) is defined as the time from cancer diagnosis to death from any cause.

Secondary outcomes

  1. Progression-free survival (PFS)

    Time frame: 1 year

    Progression-free survival (PFS) is defined as the time from the start of treatment until disease progression or the emergence of new lesions.

Study contacts

Contact information is provided by the study sponsor or research team.

Weilin Wang, PHD

CONTACT

[email protected]

+86 057187783820

Yuan Ding, PHD

CONTACT

[email protected]

+86 18858101960

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Registry information

Official study title

Chemotherapy Combined with Immunotherapy and Targeted Therapy in Advanced Intrahepatic Cholangiocarcinoma

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Dec 5, 2024
Registry last updated
Feb 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.